AstraZeneca PLC (AZN)
156.90
-0.80
(-0.51%)
USD |
NYSE |
Oct 02, 16:00
157.01
+0.11
(+0.07%)
After-Hours: 20:00
AstraZeneca Enterprise Value : 512.95B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 512.95B |
| October 01, 2026 | 515.43B |
| September 30, 2026 | 527.12B |
| September 29, 2026 | 535.62B |
| September 28, 2026 | 541.64B |
| September 25, 2026 | 542.97B |
| September 24, 2026 | 536.70B |
| September 23, 2026 | 532.89B |
| September 22, 2026 | 548.52B |
| September 21, 2026 | 547.68B |
| September 18, 2026 | 541.42B |
| September 17, 2026 | 541.60B |
| September 16, 2026 | 531.52B |
| September 15, 2026 | 528.30B |
| September 14, 2026 | 534.29B |
| September 11, 2026 | 523.09B |
| September 10, 2026 | 521.44B |
| September 09, 2026 | 513.07B |
| September 08, 2026 | 522.68B |
| September 04, 2026 | 530.94B |
| September 03, 2026 | 537.36B |
| September 02, 2026 | 527.62B |
| September 01, 2026 | 530.22B |
| August 31, 2026 | 529.17B |
| August 28, 2026 | 530.94B |
| Date | Value |
|---|---|
| August 27, 2026 | 536.58B |
| August 26, 2026 | 542.01B |
| August 25, 2026 | 552.52B |
| August 24, 2026 | 543.37B |
| August 21, 2026 | 541.11B |
| August 20, 2026 | 536.49B |
| August 19, 2026 | 537.91B |
| August 18, 2026 | 522.87B |
| August 17, 2026 | 512.91B |
| August 14, 2026 | 511.55B |
| August 13, 2026 | 514.00B |
| August 12, 2026 | 517.91B |
| August 11, 2026 | 518.68B |
| August 10, 2026 | 528.48B |
| August 07, 2026 | 526.97B |
| August 06, 2026 | 525.88B |
| August 05, 2026 | 527.21B |
| August 04, 2026 | 508.98B |
| August 03, 2026 | 516.26B |
| July 31, 2026 | 552.46B |
| July 30, 2026 | 557.73B |
| July 29, 2026 | 563.81B |
| July 28, 2026 | 561.27B |
| July 27, 2026 | 552.46B |
| July 24, 2026 | 551.28B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| GSK Plc | 114.59B |
| Johnson & Johnson | 644.86B |
| Eli Lilly & Co. | 1.122T |
| Merck & Co., Inc. | 403.00B |
| Novo Nordisk A/S | 139.42B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.076B |
| Revenue (Quarterly) | 15.26B |
| Total Expenses (Quarterly) | 12.19B |
| EPS Diluted (Quarterly) | 0.9849 |
| Gross Profit Margin (Quarterly) | 76.09% |
| Profit Margin (Quarterly) | 20.15% |
| Earnings Yield | 2.12% |
| Operating Earnings Yield | 2.87% |
| Normalized Earnings Yield | 2.147 |